This review provides a practical approach to prescribing antiplatelet therapy to mitigate the high residual risk of secondary ischemic events in patients following an acute coronary syndrome.
Answers are grounded in this paper and cite their sources.
Persistent residual risk after ACS may support intensified secondary prevention; leaves open optimal antiplatelet strategies.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Alkhalil et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: